KalVista Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, marking a significant milestone as the company generated product revenue for the first time, totaling $13.7 million. This revenue was attributed to the commercial launch of EKTERLY® (sebetralstat), an oral therapy for hereditary angioedema (HAE), following its FDA approval on July 3, 2025. In comparison, the company had no product revenue in the same quarter of the previous year. However, KalVista's operating loss widened to $46.1 million for the quarter, up from $43.5 million in the prior year, primarily due to increased selling, general, and administrative expenses.
The company's total operating expenses for the third quarter reached $59.7 million, a 37% increase from $43.5 million in the same period last year. This rise was driven by a substantial increase in selling, general, and administrative expenses, which surged by 88% to $46.5 million, reflecting the costs associated with the launch of EKTERLY. Research and development expenses decreased by 36% to $12.0 million, as the company reduced spending on sebetralstat and other R&D activities. For the nine months ended September 30, 2025, KalVista reported a net loss of $158.9 million, compared to a loss of $122.5 million for the same period in 2024.
KalVista's balance sheet showed total assets of $339.9 million as of September 30, 2025, an increase from $294.8 million at the end of 2024. The company’s cash and cash equivalents rose to $243.5 million, up from $182.3 million, bolstered by financing activities including the issuance of $143.8 million in convertible senior notes. Total liabilities increased significantly to $322.9 million, primarily due to the new convertible notes and a royalty obligation related to the DRI Healthcare agreement.
In terms of strategic developments, KalVista has expanded its geographic footprint with EKTERLY now approved in multiple regions, including the U.S., U.K., and Europe, with commercial sales initiated in the U.S. and Germany. The company also entered into a License, Supply, and Distribution Agreement with Kaken Pharmaceutical Co., Ltd. for exclusive commercialization rights in Japan, which includes an upfront payment of $11 million. Looking ahead, KalVista anticipates continued losses as it invests in the commercialization of EKTERLY and the development of additional product candidates, while maintaining sufficient liquidity to support operations for at least the next twelve months.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies for rare diseases, primarily hereditary angioedema (HAE). Its flagship product, EKTERLY (sebetralstat), is an oral on-demand treatment for HAE attacks, targeting plasma kallikrein. The company advances its pipeline through research, strategic licensing, and global regulatory efforts, competing with established biotech and pharma firms in the rare disease space. It emphasizes innovation, intellectual property, and global commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.